Nomathemba C Chandiwana
Overview
Explore the profile of Nomathemba C Chandiwana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
37
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carrillo-Larco R, Bulstra C, Manne-Goehler J, Siedner M, Johnson L, Marconi V, et al.
PLOS Glob Public Health
. 2024 Sep;
4(9):e0003640.
PMID: 39288136
It remains unclear if and how body mass index (BMI) levels have changed over time in HIV endemic regions. We described trends in mean BMI and prevalence of overweight between...
2.
Peters R, Nel J, Sadiq E, Kufa T, Smit D, Sorour G, et al.
South Afr J HIV Med
. 2024 May;
25(1):1577.
PMID: 38725703
Syphilis, 'the great imitator', caused by infection, remains a complex and multifaceted disease with a rich history of clinical diversity. This guideline aims to be a comprehensive guide for healthcare...
3.
Chandiwana N, Siedner M, Marconi V, Hill A, Ali M, Batterham R, et al.
J Clin Endocrinol Metab
. 2023 Jul;
109(2):e478-e487.
PMID: 37437159
Rapid advances in the potency, safety, and availability of modern HIV antiretroviral therapy (ART) have yielded a near-normal life expectancy for most people living with HIV (PLWH). Ironically, considering the...
4.
Mateza S, Bradford Y, Maartens G, Sokhela S, Chandiwana N, Venter W, et al.
Pharmacogenet Genomics
. 2023 Apr;
33(5):91-100.
PMID: 37099271
Objective: Renal toxicity is more common with tenofovir disoproxil fumarate (TDF) than with tenofovir alafenamide fumarate (TAF). We investigated whether polymorphisms in genes relevant to tenofovir disposition affect renal toxicity...
5.
Mondleki E, Banda C, Chandiwana N, Sokhela S, Wiesner L, Venter F, et al.
South Afr J HIV Med
. 2023 Feb;
23(1):1452.
PMID: 36751628
Background: Dolutegravir, a component of the preferred first-line antiretroviral therapy regimen, has been associated with increased weight gain. South Africa has a high prevalence of obesity, especially among women. Understanding...
6.
Chandiwana N, Serenata C, Owen A, Rannard S, Perez Casas C, Scott C, et al.
AIDS
. 2021 Dec;
35(Suppl 2):S137-S143.
PMID: 34848580
Long-acting antiretroviral drugs have emerged as exciting treatment and preexposure prophylaxis (PrEP) options for people with HIV and at risk of HIV. Long-acting regimens may improve dosing convenience, tolerability and...
7.
Cindi Z, Maartens G, Bradford Y, Venter W, Sokhela S, Chandiwana N, et al.
J Acquir Immune Defic Syndr
. 2021 Feb;
87(3):1002-1009.
PMID: 33625064
Background: Excessive weight gain affects some HIV-positive individuals prescribed dolutegravir-containing regimens. Mechanisms underlying such weight gain are unknown. Setting: Data and DNA from antiretroviral therapy-naïve participants who were randomized to...
8.
Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa
Chandiwana N, Chersich M, Francois Venter W, Akpomiemie G, Hill A, Simmons B, et al.
AIDS
. 2020 Oct;
35(2):205-211.
PMID: 33086234
Objective: Dolutegravir exposure at conception was associated with a preliminary signal of increased infant neural tube defect risk. As low maternal folate levels are linked with neural tube defects, we...